FcyRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

By Thomas Valerius, Bernhard Stockmeyer, Annemie B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik-Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki, and Jan G.J. van de Winkel

Promising results from clinical trials with unconjugated antibodies stimulated renewed interest in immune effector mechanisms of monoclonal antibodies (MoAbs). We investigated the potential of IgA as antibody isotype for cell- or complement-mediated tumor cell lysis and assessed the potential of its myeloid Fc receptor, FcyRI (CD89), as trigger molecule for bispecific antibody (BsAb)-mediated immunotherapy. Comparing hapten-directed antibodies of human IgA2 with IgG1 or IgG3 isotypes, we found all three to mediate effective killing of sensitized tumor target cells in whole blood assays. Analysis of effector mechanisms showed IgG-mediated lysis to be predominantly complement-dependent; whereas IgA-dependent killing was primarily effector cell-mediated. A comparison of effector cell populations in antibody-dependent cell-mediated cytotoxicity (ADCC) showed neutrophils to be most important for IgA-dependent tumor cell killing, involving FcyRI as shown with Fc receptor blocking antibodies. Reverse ADCC experiments against target cells sensitized with Fc receptor antibodies, or assays with FcyRI-directed bispecific antibodies confirmed FcyRI as effective trigger molecule in polymorphonuclear neutrophil (PMN)-mediated lysis. During granulocyte colony-stimulating factor (G-CSF) therapy, (FcyRI × HER-2/neu) bispecific antibodies induced enhanced killing of HER-2/neu positive SK-BR-3 breast cancer cells in whole blood assays. This enhanced cytotoxicity was paralleled by increased PMN counts, which lead to higher effector to target cell ratios in G-CSF–primed blood. Furthermore, bispecific antibodies, directed to FcyRI and Candida albicans, enhanced neutrophils’ phagocytosis of fungi. In summary, these results identify IgA as an effective antibody isotype for immunotherapy, working primarily via FcyRI on neutrophils. They suggest FcyRI-directed bispecific antibodies and G-CSF to be an attractive combination for malignant or infectious diseases.

© 1997 by The American Society of Hematology.

MONOCLONAL ANTIBODIES (MoAbs) offer the potential to increase the specificity of oncologic therapy by targeting select tumor-associated antigens.1,2 Antitumor effects of MoAb may be divided into (1) direct effects on tumor cells (such as blockade of growth factors, inhibition of proliferation, or induction of apoptosis), or (2) indirect effects. These latter involve recruitment of immune effector mechanisms such as complement- or cell-mediated lysis of target cells and require interaction of therapeutic antibodies with complement proteins or with immunoglobulin receptors on effector cells. An improved interaction was shown with chimeric or humanized antibodies relative to their murine counterparts.3,4 Recent clinical trials with MoAbs in oncology focused largely on human IgG1 as therapeutic isotype.5,6 Human IgG1 effectively activates human complement and interacts well with human IgG Fc receptors, especially FcγRIIa (CD16) involved in natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Data in this report support a role for human IgA as a promising therapeutic antibody isotype because it effectively recruits neutrophils for ADCC. Neutrophils have tumor-cytolytic potential against a broad spectrum of tumor cells10,11 and represent the most populous Fc receptor-expressing leukocytes. In addition, their number can be expanded several-fold by therapeutic application of granulocyte colony-stimulating factor (G-CSF).

Cell-mediated effects of MoAbs require binding of their Fc portions to activating Fc receptors on immune effector cells. Most Fc receptors belong to the family of multichain immune recognition receptors (MIRR), consisting of distinct ligand binding α-chains, which noncovalently associate with shared signaling components. These promiscuous signaling molecules include FcR γ-, β-, or ζ-chains.11,12 For the family of leukocyte IgG receptors, eight α-chain genes were identified, all located on chromosome 1. They encode a total of 12 transmembrane or soluble receptor isoforms, which are grouped based on genetic, biochemical, and functional characteristics, into three Fcγ receptor classes: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). For IgA, in comparison, one α gene (FcγRI), located on chromosome 19, has been characterized that encodes several alternatively spliced transmembrane isoforms of 55 to 110 kD.13,15 FcyRI (CD89) is constitutively expressed on monocytes/macrophages, eosinophilic and neutrophilic granulocytes, but importantly, not on noneffector cell populations. FcyRI has medium affinity (≈5 × 10^7 mol/L) for both IgG1 and IgA2,16,17 which is increased on exposure to G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF).18 For signaling, the α-chain of the IgA receptor requires association with the common FcγRγ-chain, which results in the phosphorylation of an ITAM (immunoreceptor tyrosine-based activation motif) within the γ-chain, initiating further downstream signaling events.19 Functions described for FcyRI include ADCC, phagocytosis, induction of a respiratory burst, and inflammatory mediator or cytokine release.16,17

In vivo, therapeutic antibodies compete with high concentrations of endogenous immunoglobulins for binding to Fc receptors. In addition, many Fc receptor-expressing cells are blocked by targeting select tumor-associated antigens.1,2 Antitumor effects of MoAb may be divided into (1) direct effects on tumor cells (such as blockade of growth factors, inhibition of proliferation, or induction of apoptosis), or (2) indirect effects. These latter involve recruitment of immune effector mechanisms such as complement- or cell-mediated lysis of target cells and require interaction of therapeutic antibodies with complement proteins or with immunoglobulin receptors on effector cells. An improved interaction was shown with chimeric or humanized antibodies relative to their murine counterparts.3,4 Recent clinical trials with MoAbs in oncology focused largely on human IgG1 as therapeutic isotype.5,6 Human IgG1 effectively activates human complement and interacts well with human IgG Fc receptors, especially FcγRIIa (CD16) involved in natural killer (NK) cell-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Data in this report support a role for human IgA as a promising therapeutic antibody isotype because it effectively recruits neutrophils for ADCC. Neutrophils have tumor-cytolytic potential against a broad spectrum of tumor cells10,11 and represent the most populous Fc receptor-expressing leukocytes. In addition, their number can be expanded several-fold by therapeutic application of granulocyte colony-stimulating factor (G-CSF).

Cell-mediated effects of MoAbs require binding of their Fc portions to activating Fc receptors on immune effector cells. Most Fc receptors belong to the family of multichain immune recognition receptors (MIRR), consisting of distinct ligand binding α-chains, which noncovalently associate with shared signaling components. These promiscuous signaling molecules include FcR γ-, β-, or ζ-chains.11,12 For the family of leukocyte IgG receptors, eight α-chain genes were identified, all located on chromosome 1. They encode a total of 12 transmembrane or soluble receptor isoforms, which are grouped based on genetic, biochemical, and functional characteristics, into three Fcγ receptor classes: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16). For IgA, in comparison, one α gene (FcγRI), located on chromosome 19, has been characterized that encodes several alternatively spliced transmembrane isoforms of 55 to 110 kD.13,15 FcyRI (CD89) is constitutively expressed on monocytes/macrophages, eosinophilic and neutrophilic granulocytes, but importantly, not on noneffector cell populations. FcyRI has medium affinity (≈5 × 10^7 mol/L) for both IgG1 and IgA2,16,17 which is increased on exposure to G-CSF or granulocyte-macrophage colony-stimulating factor (GM-CSF).18 For signaling, the α-chain of the IgA receptor requires association with the common FcγRγ-chain, which results in the phosphorylation of an ITAM (immunoreceptor tyrosine-based activation motif) within the γ-chain, initiating further downstream signaling events.19 Functions described for FcyRI include ADCC, phagocytosis, induction of a respiratory burst, and inflammatory mediator or cytokine release.16,17

In vivo, therapeutic antibodies compete with high concentrations of endogenous immunoglobulins for binding to Fc receptors. In addition, many Fc receptor-expressing cells are

From the Department of Medicine III, University of Erlangen, Nürnberg, Germany; Medarex, Annandale, NJ; Medarex Europe, Utrecht, The Netherlands; the Department of Immunology, University of Birmingham, Birmingham, UK, and the Department of Immunology, University Hospital Utrecht, Utrecht, The Netherlands.

Submitted May 12, 1997; accepted July 24, 1997.

Supported by the Deutsche Forschungsgemeinschaft, Bonn, Germany (Va 124/1-3).

Address reprint requests to Thomas Valerius, MD, Division of Hematology/Oncology, Department of Medicine III, University Erlangen, Nürnberg, Krankenhausstraße 12, 91054 Erlangen, Germany.

The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. section 1734 solely to indicate this fact.

© 1997 by The American Society of Hematology. 0006-4977/97/0011-0019$3.00/0

Blood, Vol 90, No 11 (December 1), 1997: pp 4485-4492

AID Blood 0031 / Sh43$5601 10-29-97 23:54:47 blda WBS: Blood
not cytolytic for tumor cells (eg, B cells, platelets), and some Fc receptor isoforms (eg, FcγRIIb, FcγRIIIb) bind antibodies, but do not trigger cytolytic cascades. However, select cytotoxic Fc receptors on effector cells can be triggered by antibodies reacting with Fc receptors via their variable regions, a process called reverse ADCC. This mechanism is used in the therapeutic concept of bispecific antibodies, where antibodies directed to cytotoxic trigger molecules, such as Fc receptors, are genetically or chemically linked to tumor-directed antibodies. Bispecific antibodies engaging FcγRI or FcγRIII are currently being tested with promising results in clinical trials and may help to overcome some of the above-mentioned limitations of conventional antibodies.

Besides their potential as effector cells in antibody-based tumor therapy, neutrophils are the main effector cell population in the host defense against fungi. Therefore, we investigated the role of bispecific antibodies directed to FcαRI and Candida albicans. These constructs were found to mediate very effective phagocytosis of Candida by neutrophils. Thus, we identify FcαRI as a promising trigger molecule for bispecific antibody (BsAb)-based therapy and show synergistic effects in combination with G-CSF.

**MATERIALS AND METHODS**

**Blood donors.** Experiments reported here were approved by the Ethical Committee of the University of Erlangen, Nürnberg, in accordance with the Declaration of Helsinki. After informed consent, 10 to 20 mL of citrate anticoagulated peripheral blood was drawn from healthy volunteers or from patients receiving G-CSF therapy. Patients were treated with rh-met-G-CSF (Neupogen, 3 to 5 μg/kg of body weight) from Hoffmann La-Roche (Basel, Switzerland), based on clinical indications. As the kinetics of neutrophil recovery during G-CSF treatment vary, the following criteria were defined for analysis: (1) at least 3 days of G-CSF treatment, and (2) absolute neutrophil count > 2,500/μL. Total leukocyte counts were determined on a Coulter cytometer (Coulter, Hialeah, FL), and absolute polymorphonuclear neutrophil (PMN) counts were calculated from total leukocyte counts and differentials of Wright-stained blood smears.

**Cell lines.** The human breast carcinoma cell line SK-BR-3 and the hybridoma cell line HB58 were obtained from the American Type Culture Collection (ATCC, Rockville, MD). All cells were kept in RPMI 1640 medium (Life Technologies, Paisley, UK) supplemented with 10% heat-inactivated fetal calf serum (FCS), 100 U/mL penicillin, 100 U/mL streptomycin, and 4 mM L-glutamine (all Life Technologies). Experiments reported here were approved by the Ethical Committee of the University of Erlangen, Nürnberg, in accordance with the Declaration of Helsinki. After informed consent, 10 to 20 mL of citrate anticoagulated peripheral blood was drawn from healthy volunteers or from patients receiving G-CSF therapy. Patients were treated with rh-met-G-CSF (Neupogen, 3 to 5 μg/kg of body weight) from Hoffmann La-Roche (Basel, Switzerland), based on clinical indications. As the kinetics of neutrophil recovery during G-CSF treatment vary, the following criteria were defined for analysis: (1) at least 3 days of G-CSF treatment, and (2) absolute neutrophil count > 2,500/μL. Total leukocyte counts were determined on a Coulter cytometer (Coulter, Hialeah, FL), and absolute polymorphonuclear neutrophil (PMN) counts were calculated from total leukocyte counts and differentials of Wright-stained blood smears.

**Fig 1.** Schematic representation of different types of cytotoxicity assays employed in this study. (A) Shows conventional ADCC against haptenized SK-BR–3 breast cancer cells via NIP-directed antibodies. FcR blocking antibodies served to identify trigger molecules involved in IgA-mediated ADCC. In (B), a novel reverse ADCC assay is shown using hybridoma target cells, which were selected for high membrane expression of their surface Ig directed to mouse k light chains. In the presence of Fc receptor antibodies, these hybridoma cells are sensitized for reverse ADCC. (C) Shows recruitment of Fc receptor positive effector cells via BsAbs.
characterization by high-performance liquid chromatography (HPLC), samples were sterilized by filtration. For production of (FcαRI × Candida) BsAb, F(ab′)2 fragments of a polyclonal anti-Candida IgG isolated from immunized rabbits (Biodesign, Kennebunk, MA) were treated with sulfo-SMCC, which adds maleimide groups to free amino groups. These F(ab′)2 fragments were then reacted with an equimolar concentration of A77 F(ab′)2, and the conjugate was purified from uncoupled molecules by chromatography on Superdex 200 (Pharmacia, Piscataway, NJ). Both BsAb were stored at 4°C and showed binding to both effectors and targets consistent with the specificity patterns of the parental antibodies.

Isolation of mononuclear and neutrophil effector cells. Isolated neutrophils were obtained by a method described by Elsasser et al.9 Briefly, citrate anticoagulated blood was layered over a discontinuous Percoll (Seromed, Berlin, Germany) gradient. After centrifugation, neutrophils were collected at the interphase between the two Percoll layers and mononuclear cells from the Percoll/plasma interface. Remaining erythrocytes were removed by hypotonic lysis. Purity of neutrophils was determined by cytoospin preparations and exceeded 95%, with few contaminating eosinophils, and less than 1% mononuclear cells. Viability of cells tested by Trypan blue exclusion was always greater than 95%.

Immunofluorescence analysis. Isolated neutrophils, mononuclear cells (MNC) or SK-BR-3 breast cancer cells were incubated with MoAb. During incubation of effector cells with MoAb, polyclonal human IgG (4 mg/mL) was added to inhibit nonspecific binding to FcγRI. After staining with FITC-labeled reagents, fluorescence was analyzed on an EPICS Profile flow cytometer (Coulter). For each cell population, relative fluorescence intensity (RFI) was calculated as the ratio of mean linear fluorescence intensity of relevant, isotype-matched antibodies.

Antibody-dependent cellular cytotoxicity assays. ADCC assays were performed as described.36 Briefly, target cells were labeled with 200 μCi 111In for 2 hours. For assays with NIP antibodies, SK-BR-3 cells were then haptenized by adding 0.5 mg of 3-nitro-4-hydroxy-5-isophenacylazetidic acid (succinimidyl ester of NIP-CAP-OSU, Genosys Biotechnologies, Cambridge, UK) dissolved in 7.5 μL of dimethyl sulfoxide (DMSO) to a 5-mL suspension of SK-BR-3 cells in borate buffer (pH 8.3). After 5 minutes at room temperature, the reaction was stopped by washing with RF100. Cells were then adjusted to 10^5/mL. Whole blood, plasma, or isolated effector cells (50 μL), sensitizing antibodies (10 μg/mL for anti-NIP IgG antibodies, 50 μg/mL for anti-NIP IgA, or 0.4 μg/mL for BsAbs, unless specified otherwise) and RF100 were added into round-bottom microtiter plates. In some experiments, Fc receptor blocking antibodies were used at a final concentration of 10 μg/mL. Assays were started by adding target cell suspensions (50 μL), giving a final volume of 200 μL, and an effector to target cell ratio of 80:1 with isolated cells. After 3 hours at 37°C, assays were stopped by centrifugation, and 51Cr release from triplicates was measured. Percentage of cellular cytotoxicity was calculated using the formula:

\[
\text{% Specific Lysis} = \frac{\text{Experimental cpm} - \text{Basal cpm}}{\text{Maximal cpm} - \text{Basal cpm}} \times 100
\]

with maximal 51Cr release determined by adding perchloric acid (3% final concentration) to target cells, and basal release measured in the presence of sensitizing antibodies without effector cells. For analysis of effects induced by Fc receptor antibodies, “% inhibition” was calculated:

\[
\text{% Inhibition} = \frac{\text{% Lysis Without FcR Antibody} - \text{% Lysis With FcR Antibody}}{\text{% Lysis Without FcR Antibody}} \times 100
\]

Negative values determined by this formula are reported as “% stimulation” in the presence of Fc receptor antibody.

Candida phagocytosis. C. albicans (strain ATCC 44858) was cultured overnight at 37°C in Sabouraud Maltose Broth (DIFCO, Detroit, MI), harvested by centrifugation, washed three times with phosphate-buffered saline (PBS), and labeled by incubation with FITC (Sigma, St Louis, MO) at a concentration of 0.1 mg/mL in 0.1 mol/L NaH2PO4/Na2HPO4 buffer (pH 9.6) for 30 minutes at 4°C. After three washes with PBS, 5 × 10^4 yeast particles were incubated for 30 minutes at 37°C with 2 × 10^3 isolated PMN without or with 10 μg/mL (A77 × αCandida) BsAbs. C. albicans phagocytosis was quantitated by measuring FITC-fluorescence intensities of cells on a flow cytometer using phycoerythrin (PE)-conjugated CD11b MoAb (Becton Dickinson, San Jose, CA) as a gate marker for PMN. Alternatively, phagocytosis was determined in cytosin preparations evaluated by microscopy.

Statistical analysis. Group data are reported as mean ± standard error of the mean (SEM). Differences between groups were analyzed by unpaired (or, when appropriate, paired) Student’s t-test. Levels of significance are indicated.

RESULTS AND DISCUSSION

To investigate the role of IgA and its myeloid receptor FcαRI (CD89) for antibody-based tumor therapy, different
cytotoxicity assays were established, which are schematically represented in Fig 1. First, SK-BR–3 breast cancer cells were covalently coated with the hapten NIP and sensitized with NIP-specific chimeric antibodies of human IgA2, IgG1, or IgG3 isotypes (Fig 1A). All three antibodies gave high levels of target cell sensitization (RFI = 130, 276, or 238, respectively) and did not induce direct target cell killing. In the presence of whole blood, all three mediated effective target cell lysis. For further analysis of effector mechanisms, whole blood was fractionated into plasma, isolated PMN, or MNC effector cells, which were then compared for their capacity to mediate lysis via NIP antibodies (Fig 2). Remarkably, IgA2-induced killing was predominantly mediated by PMN, and to a smaller extent, by plasma or MNC effector cells. In contrast, IgG1- or IgG3-mediated killing resided predominantly in the plasma fraction, with significant cell-mediated lysis only observed with IgG1. Antibody-mediated lysis in the presence of plasma was completely abrogated when plasma was heat-inactivated at 56°C for 30 minutes (n = 3), indicating complement-mediated lysis to be the underlying effector mechanism. In accordance with previous reports, IgA was found to be less effective than IgG1 in complement-dependent target cell killing. However, uncontrolled complement activation induced by therapeutic antibodies in vivo may cause serious side effects in patients. On the other hand, IgA proved considerably more effective in recruiting PMN for ADCC than IgG1. To our knowledge, no therapeutic human IgA MoAb has yet been produced.

Fig 3. The role of FcγRI (CD89) in PMN-mediated ADCC was investigated by using Fc receptor-blocking antibodies in NIP-IgA2–mediated ADCC against SK-BR–3 cells (A) and in reverse ADCC against HB58 target cells (B). Significant inhibition of ADCC was observed with antibody My43 to FcγRI, but not with antibodies 197, IV.3 or 3G8 to FcγRII, FcγRIII, respectively. Data from four experiments are presented as mean ± SEM of % specific inhibition. For reverse ADCC assays (B), HB58 hybridoma cells were selected for high membrane expression of their surface immunoglobulin, which is directed against mouse κ light chain, leading to sensitization of targets in the presence of murine antibodies against potential cytotoxic trigger molecules on PMN. In these experiments, PMN were effective with FcγRI or FcγRII-directed antibodies, but not with antibodies to FcγRI or FcγRIII. Results from five experiments are presented as mean ± SEM of % specific lysis. Significant (P < .05) inhibition (A) or reverse ADCC (B) is marked by an asterisk (*).
Fig 5. Isolated neutrophils from healthy donors or from G-CSF-treated patients were compared for expression of FcεRI (A), conventional ADCC via IgA2 (B), or reverse ADCC using either A77 sensitized HB58 target cells (C), or FcεRI-directed BsAb (D). Both effector cell populations expressed similar levels of FcεRI. At constant effector to target cell ratios, G-CSF–primed PMN were less effective than healthy donor PMN, with differences being significant for ADCC against SK-BR–3, either haptenized using anti-NIP IgA or HER-2/neu-directed BsAb (P = .01, or .03, respectively). Results from at least eight experiments are expressed as mean ± SEM. (A) (●), Relevant antibody; (□), irrelevant antibody. (B through D) (●), Healthy donor; (□), G-CSF–treated patient.

given to patients. Together with our previous observation that neutrophil-mediated ADCC against malignant B cells was strongly target antigen restricted, results reported here suggest IgA antibodies to be particularly promising when ADCC by neutrophils is a major effector mechanism for MoAbs. Further studies are in progress to investigate whether neutrophils’ target antigen restriction can be overcome by using therapeutic antibodies of IgA isotype.

To identify cellular receptors involved in IgA-mediated ADCC, we analyzed PMNs’ expression of FcεRI (CD89), FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16) by indirect immunofluorescence with MoAb A77, 22, IV.3, or 3G8, respectively. Thus, PMN expressed FcεRI, FcγRII, and FcγRIII (RFI 11.0 ± 1.1, 16.5 ± 2.2, and 99.1 ± 20.5, respectively, n = 8), but very low levels of FcγRI (RFI = 1.6 ± 0.2, n = 8). Blocking antibodies to FcγRI (197, whole antibody), FcγRII (IV.3, F(ab) fragments), FcγRIII (3G8, F(ab’) fragments), or FcεRI (My43, whole antibody) served to identify trigger molecules on PMN involved in IgA-mediated killing. IgA-mediated ADCC by PMN was significantly (P < .05) inhibited by FcεRI antibody My43, but not by isotype control antibodies or by Fcγ receptor antibodies, which were documented to block IgG-mediated ADCC11,12 (Fig 3A).

Reverse ADCC, induced by antibodies directed against surface molecules on effector cells, represents a sensitive and specific approach to identify tumor-cytolytic trigger molecules. To compare different Fc receptors for their capacity to mediate reverse cytotoxicity, we set-up a novel assay using rat HB58 hybridoma cells as targets in ADCC (Fig 1B). These cells were selected for high membrane expression of their surface immunoglobulin, a rat antibody directed to mouse k light chains. In the presence of murine effector cell-directed antibodies, these target cells are sensitized for reverse ADCC. Importantly, healthy donor PMN very effectively lysed HB58 hybridoma cells in the presence of FcεRI antibody A77 (Fig 3B). Furthermore, they were effective with FcγRIII antibody IV.3, but not with FcγRI or FcγRII antibodies (22, and 3G8, respectively). G-CSF primed PMN were additionally effective with FcγRI antibody 22 (not shown). Data with this broadly applicable assay establish FcεRI on PMN as novel cytotoxic trigger molecule. For
Fig 7. Role of FcαRI (CD89) in PMN-mediated phagocytosis of fungi. PMN were cultured with C. albicans in medium alone (A and C) or in the presence of (A77 × αCandida) BsAb (B and D). Phagocytosis was analyzed microscopically with (A and B) showing representative photographs or by flow cytometry (C and D), plotting FITC-fluorescence (arbitrary units on a logarithmic scale) against the relative cell number. These experiments were repeated three times yielding essentially identical results.

Fcγ receptors, they are in agreement with results using Fc receptor-specific hybridoma targets in reverse ADCC assays, which were selected for high surface expression of their immunoglobulins.9,33

The mechanism of reverse ADCC is exploited in the therapeutic concept of bispecific antibodies (Fig 1C). We, therefore, tested a BsAb constructed by chemically cross-linking F(ab′) fragments of antibodies A77 and 520C9, specific for FcαRI (CD89), or the proto-oncogene protein HER-2/neu, respectively. This BsAb showed the expected binding characteristics and was tested in ADCC against HER-2/neu positive SK-BR-3 breast cancer cells (Fig 4) using either whole blood (Fig 4A), or fractions consisting of human plasma, isolated MNC or PMN effector cells (Fig 4B). As shown, (A77 × 520C9) BsAb induced significant target cell lysis at concentrations higher than 80 pg/mL, with optimal killing at 2.0 μg/mL, by whole blood or PMN. Isolated MNC or human plasma had no activity with this BsAb, indicating that reverse ADCC by PMN represents the predominant effector mechanism in these whole blood assays.

G-CSF is known to stimulate IgG-dependent ADCC by PMN via induction of FcγRI expression34 and to increase the affinity of IgA binding.18 Therefore, we compared isolated PMN from healthy donors and from patients during G-CSF therapy (Fig 5) for FcαRI expression (Fig 5A), IgA-mediated ADCC against haptenized targets (Fig 5B), reverse
ADCC against A77-sensitized HB58 hybridoma cells (Fig 5C), and (A77 × 520C9) BsAb mediated lysis of SK-BR-3 cells (Fig 5D). As reported before,34,35 PMN isolated from patients during G-CSF therapy expressed higher levels of FcγRII compared with healthy donor PMN (RFI 8.1 ± 1.3 vs. 1.6 ± 0.2, n = 5, P < .01). However, both effector cell populations expressed similar levels of FcαRI (RFI 11.0 ± 1.1 vs. 16.2 ± 3.1, n = 12, P = .09). In ADCC assays (at constant effector to target cell ratios), G-CSF–primed PMN were less effective than healthy donor PMN, with differences being significant for ADCC against SK-BR-3, either haptenized using anti-NIP IgA or HER-2/neu directed BsAb (P = .01, or .03, respectively). This may be explained by competition for FcγRI γ-chain association between FcαRI and upregulated FcγRII on G-CSF–primed PMN, as has been shown for other Fc receptors.36,37 An alternative explanation is regulated expression of different FcγR isoforms, leading to expression of isoforms with reduced affinity for IgA13 or diminished signaling capacity.14 As ADCC is critically dependent on effector to target cell ratios,10 we performed whole blood ADCC assays before, on days 3 and 7 during, and after G-CSF therapy (Fig 6). Consistent with a critical role for PMN in FcαRI-mediated ADCC, increases in neutrophil counts were closely paralleled by significantly enhanced lysis of SK-BR-3 breast cancer cells in the presence of (FcαRI × HER-2/neu) BsAb.

Neutrophils are the most important effector cell population against pathogenic fungi such as candida and aspergillus species.23,24 Therefore, we investigated the role of FcαRI in mediating Candida phagocytosis by neutrophils. As shown in Fig 7, very effective phagocytosis of Candida was observed in the presence of (FcαRI × αCandida) BsAb. Comparing G-CSF–primed and healthy donor PMN, 59.4% ± 7.1% versus 62.7% ± 8.1% of neutrophils had phagocytosed Candida in the presence of BsAb (n = 3, difference not significant), whereas in its absence, only 3.9% ± 1.9% versus 7.5% ± 2.4% of PMN had ingested yeast particles.

In summary, these results suggest IgA antibodies or FcαRI-directed BsAbs to be effective reagents for immunotherapy, working primarily by recruiting PMN for ADCC or phagocytosis. The safety of G-CSF to increase neutrophil numbers in combination with (FcγRI × HER-2/neu) BsAb is currently evaluated in phase II/III studies.38,39 Preliminary results from these trials show biological responses, such as release of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), and an acceptable toxicity profile.38,39 Results reported here suggest combinations of FcαRI-directed BsAb and G-CSF to be promising for clinical evaluation.

ACKNOWLEDGMENT

We acknowledge the excellent technical assistance by S. Gehr and B. Bock, and H. Vile and K. Sundarapandian for preparation of bspecific antibodies. We thank Dr R.J. Owens for his support generating chimeric anti-NIP IgG1 and IgG3 transfectomas and Dr P. Guyre for valuable comments on the manuscript.

REFERENCES

1. Dillman RO: Antibodies as cytotoxic therapy. J Clin Oncol 12:1497, 1994

2. Grossbard ML, Press OW, Appelbaum FR, Bernstein JD, Nadler LM: Monoclonal antibody-based therapies of leukemia and lymphoma. Blood 80:863, 1992

3. Brüggemann M, Williams GT, Bindon CI, Clark MR, Walker MR, Jeffers R, Waldmann H, Neuberger MS: Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 166:1351, 1987

4. Reichmann L, Clark M, Waldmann H, Winter G: Reshaping human antibodies for therapy. Nature 332:323, 1988

5. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Huids CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L: Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with advanced breast or ovarian cancer that expresses the proto-oncogene HER-2/neu. J Clin Oncol 14:737, 1996

6. McLaughlin P, Grillo-Lopez AJ, Cucuzman M, Link BK, Levy R, Dillman RO, Ho A, Bennett JM, Heyman MR, Schilder RJ, Cabanillas F, Rogers J, DallaIRE: Preliminary report on a phase III pivotal trial of the anti-CD20 antibody IDEC-C2B8 in patients with relapsed low-grade or follicular lymphoma. Proc Am Soc Clin Oncol 15:417, 1996 (abstr)

7. Lichtenstein A: Granulocytes as possible effectors of tumor immunity, in Oetgen HF (ed): Human Cancer Immunology I. Philadelphia, PA, Saunders, 1990, p 731

8. Musiani P, Modesti A, Gioverelli M, Cavalllo F, Colombo MP, Lollini PL, Forni G: Cytokines, tumour-cell death and immunogenicity: A question of choice. Immunol Today 18:32, 1997

9. Elissäser D, Valerius T, Repp R, Weiner GJ, Deo Y, Kalden JR, Van de Winkel JG, Stevenson GT, Glennie MJ, Gratzmairi: HLA class II as potential target antigen on malignant B cells for therapy with bspecific antibodies in combination with G-CSF. Blood 87:3803, 1996

10. Stockmeyer B, Valerius T, Repp R, Heijnen IAFM, Bühring HJ, Deo YM, Kalden JR, Gratzmairi M, Van de Winkel JG: Preclinical studies with FcyRI bspecific antibodies and G-CSF primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer. Cancer Res 57:696, 1997

11. Ravetch JV, Kinet JP: Fc receptors. Ann Rev Immunol 9:457, 1991

12. Van de Winkel JG, Capel PJA: Human IgG Fc receptor heterogeneity: Molecular aspects and clinical implications. Immunol Today 14:215, 1993

13. Pleiss RJ, Andrews PD, Kerr MA, Woof JM: Alternative splicing of the human IgA Fc receptor CD89 in neutrophils and eosinophils. Biochem J 318:771, 1996

14. van Dijk TB, Bracke M, Caldenhoven E, Raaijmakers JAM, Lammers JWJ, Koenderman L, de Groot RP: Cloning and characterisation of FcαRI, a novel Fc receptor (CD89) isoform expressed in eosinophils and neutrophils. Blood 88:4229, 1996

15. Morton HC, Schiel AE, Janssen SWJ, Van de Winkel JGJ: Structure and function of human IgA Fc receptors (FcαR). Crit Rev Immunol 16:423, 1996

16. Weisburth RH, Kacena A, Schuh A, Golde DW: GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature 332:647, 1988

17. Morton HC, van den Herik-Oudijk IE, Vossebeld P, Snijders A, Verhoeven AJ, Capel PJA, Van de Winkel JGJ: Functional association between the human myeloid IgA Fc receptor (CD89) and the Fcγ chain. Molecular basis for CD89/Fcγ chain association. J Biol Chem 270:29781, 1995
20. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on FcγRI are able to trigger receptor function. J Immunol 143:1650, 1989
21. Fanger MW, Morganelli PM, Guyre PM: Bispecific antibodies. Crit Rev Immunol 12:101, 1992
22. Deo YM, Graziano RF, Repp R, Van de Winkel JGJ: Clinical significance of IgG receptors and FcγR-directed immunotherapies. Immunol Today 18:127, 1997
23. Pizzo PA: Granulocytopenia and cancer therapy: Past problems, current solutions, future challenges. Cancer 54:2649, 1984
24. Schaffner A, Davis CE, Schaffner T, Markert M, Douglas H, Braude AI: In vitro susceptibility of fungi to killing by neutrophil granulocytes discriminates between primary pathogenicity and opportunism. J Clin Invest 78:511, 1986
25. Lund I, Takahashi N, Pound JD, Goodall M, Jeffers R: Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fcγ receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 157:4963, 1996
26. Ring DB, Kassel JA, Hsieh-Ma ST, Bjorn MJ, Tringale F, Eaton AM, Reid SA, Frankel AE, Nadji M: Distribution and physical properties of BCA200, a Mr 200,000 glycoprotein selectively associated with human breast cancer. Cancer Res 49:3070, 1989
27. Monteiro RC, Cooper MD, Kubagawa H: Molecular heterogeneity of Fcε receptors detected by receptor-specific monoclonal antibodies. J Immunol 148:1764, 1992
28. Shen L, Lasser R, Fanger MW: My 43, a monoclonal antibody that reacts with human myeloid cells inhibits monocyte IgA binding and triggers function. J Immunol 143:4117, 1989
29. Looney RJ, Abraham GN, Anderson CL: Human monocytes and U937 cells bear two distinct Fc receptors for IgG. J Immunol 136:1641, 1986
30. Fleit HB, Wright SD, Unkeless JC: Human neutrophil Fcγ receptor distribution and structure. Proc Natl Acad Sci USA 79:3275, 1982
31. Glennie MJ, Tutt AL, Greenman J: Preparation of multispecific F(ab’), and F(ab’), antibody derivates, in Gallagher G, Rees RC, Reynolds CW (eds): Tumour Immunobiology, A Practical Approach. Oxford, UK, Oxford University Press, 1995, p 225
32. Marx JL: Suppressing autoimmunity in mice. Science 221:843, 1983
33. Graziano RF, Fanger MW: Human monocyte-mediated cytotoxicity: The use of Ig-bearing hybridomas as target cells to detect trigger molecules on the monocyte cell surface. J Immunol 138:945, 1987
34. Valerius T, Repp R, de Wit TPM, Berthold S, Platzer E, Kalden JR, Gramatzki M, Van de Winkel JGJ: Involvement of the high affinity receptor for IgG (FcγRI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during G-CSF therapy. Blood 82:931, 1993
35. Repp R, Valerius T, Sendler A, Gramatzki M, Iro H, Kalden JR, Platzer E: Neutrophils express the high affinity receptor for IgG (Fc-gamma RI; CD64) after in vivo application of rhG-CSF. Blood 78:885, 1991
36. Heijnen IAFM, van Vugt MJ, Fanger NA, Graziano RF, de Wit TPM, Hofhuis FMA, Guyre PM, Capel PJA, Verbeek JS, Van de Winkel JGJ: Antigen targeting to myeloid-specific human FcγRI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest 97:331, 1996
37. Dombrowicz D, Flamand V, Miyajima I, Ravetch JV, Galli SJ, Kinet JP: Absence of FcεRIα chain results in upregulation of FcεRIII-dependent mast cell degranulation and anaphylaxis; evidence of competition between FcεRI and FcγRIII for limiting amounts of FcR β and γ chains. J Clin Invest 99:915, 1997
38. Weber JS, Spears L, Deo Y, Link JL: Phase I study of a HER-2/neu bispecific antibody with G-CSF in patients with metastatic breast cancer. Proc Am Sci Clin Oncol 15:354, 1996 (abstr)
39. Valerius T, Repp R, Wieland G, Deo Y, Van de Winkel JGJ, Kalden JR, Lang N, Gramatzki M: Bispecific antibody MDX210 (FcγRI × HER-2/neu) in combination with G-CSF: Results of a phase I trial in patients with metastatic breast cancer. Proc Am Sci Clin Oncol 15:108, 1996 (abstr)
FcαRI (CD89) as a Novel Trigger Molecule for Bispecific Antibody Therapy

Thomas Valerius, Bernhard Stockmeyer, Annemiek B. van Spriel, Robert F. Graziano, Ingrid E. van den Herik-Oudijk, Roland Repp, Yashwant M. Deo, John Lund, Joachim R. Kalden, Martin Gramatzki and Jan G.J. van de Winkel